U.S. markets close in 5 hours 6 minutes
  • S&P 500

    -19.97 (-0.53%)
  • Dow 30

    -182.27 (-0.59%)
  • Nasdaq

    -66.07 (-0.60%)
  • Russell 2000

    -15.19 (-0.89%)
  • Crude Oil

    +1.73 (+1.64%)
  • Gold

    -6.30 (-0.35%)
  • Silver

    -0.74 (-3.62%)

    -0.0093 (-0.88%)
  • 10-Yr Bond

    -0.1430 (-4.81%)

    -0.0172 (-1.41%)

    -0.6600 (-0.49%)

    +342.47 (+1.80%)
  • CMC Crypto 200

    -3.70 (-0.88%)
  • FTSE 100

    -36.68 (-0.51%)
  • Nikkei 225

    -457.42 (-1.73%)

Edwards Lifesciences (EW) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Edwards Lifesciences (EW) closed at $90.79 in the latest trading session, marking a +1.62% move from the prior day. This move outpaced the S&P 500's daily loss of 0.13%. Meanwhile, the Dow lost 0.15%, and the Nasdaq, a tech-heavy index, added 0.14%.

Coming into today, shares of the medical device maker had lost 5.5% in the past month. In that same time, the Medical sector lost 5.23%, while the S&P 500 lost 3.32%.

Investors will be hoping for strength from Edwards Lifesciences as it approaches its next earnings release. On that day, Edwards Lifesciences is projected to report earnings of $0.64 per share, which would represent no growth from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.4 billion, up 1.92% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.57 per share and revenue of $5.72 billion. These totals would mark changes of +15.77% and +9.29%, respectively, from last year.

Any recent changes to analyst estimates for Edwards Lifesciences should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.13% higher. Edwards Lifesciences is currently sporting a Zacks Rank of #3 (Hold).

Looking at its valuation, Edwards Lifesciences is holding a Forward P/E ratio of 34.82. For comparison, its industry has an average Forward P/E of 25.85, which means Edwards Lifesciences is trading at a premium to the group.

We can also see that EW currently has a PEG ratio of 2.51. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. EW's industry had an average PEG ratio of 1.88 as of yesterday's close.

The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 176, putting it in the bottom 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.